Baxter International Inc.

NYSE:BAX

Medical - Instruments & Supplies

Healthcare
$26.16 -5.23%

-$1.07 today

Market cap
$13.53B
Beta
0.64
P/E (TTM)
-9.1
EPS (TTM)
-$2.13
Dividend yield
1.03%
52W Low $15.73High $31.76

Volume 4.01M

Average 7.62M

BAX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Baxter International Inc.NYSE: BAX

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense grows, but more slowly than its trailing trend

Q2 FY2026 income tax expense of $23M rose 109.1% year over year, behind the +698.8% change in trailing-twelve-month income tax expense. Sequentially, it rose 109.1% from the prior quarter.

Context

  • Income tax expense amounted to 3.5% of revenue in FY2025, up 3.2 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +109.1% toward the trailing-twelve-month pace of +698.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$23M+109.1% QoQ
Last fiscal yearDec 2025
$395M+967.6% YoY
LTMJun 2026
$485M+698.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+109.1%——
1 year+967.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
395M USD
Year-over-year change
+967.6%
4-year CAGR
+47.7%

Income Tax Expense vs competitors

How BAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +698.8% is the highest of 5, against a peer median of +1.9%.
  • Income tax expense amounts to 4.2% of revenue for BAX, versus a peer median of 1.9%.
BAX Competitors
Income Tax Expense for BAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BAXBaxter International Inc.LTM Jun 2026$485M USD+698.8%—4.2%
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€314.25M EUR-0.8%-0.4%1.6%
DVADaVita Inc.LTM Jun 2026$303.27M USD+4.6%+14.0%2.2%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$3.88M USD+13.3%+229.2%2.7%
ICUIICU Medical, Inc.LTM Jun 2026-$30.96M USD-158.6%—1.4%
Peer median (excluding BAX) —+1.9%+14.0%1.9%

Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.15B10.06B10.36B10.64B11.24B
Cost of Revenue7.43B6.51B6.21B6.65B7.87B
Gross Profit4.72B3.55B4.15B3.98B3.38B
Gross Margin38.9%35.3%40.1%37.5%30.1%
Research & Development531M450M518M590M518M
Selling, General & Admin2.85B3.1B2.95B2.97B2.89B
Operating Expenses3.37B6.39B3.44B3.97B3.69B
Depreciation & Amortization867M1.07B984M997M981M
EBITDA2.19B(1.76B)1.73B1.12B766M
EBITDA Margin18.0%-17.5%16.7%10.5%6.8%
Operating Income1.35B(2.85B)707M14M(308M)
Operating Margin11.1%-28.3%6.8%0.1%-2.7%
Interest Income14M19M69M67M52M
Interest Expense207M413M508M408M290M
Other Income / Expenses(234M)(403M)(465M)(303M)(197M)
Income Before Tax1.12B(3.25B)242M(289M)(505M)
Pre-Tax Margin9.2%-32.3%2.3%-2.7%-4.5%
Income Tax Expense83M(135M)61M37M395M
Net Income1.28B(2.43B)2.66B(649M)(957M)
Net Margin10.6%-24.2%25.6%-6.1%-8.5%
EPS (Basic)2.56(4.83)5.25(1.27)(1.75)
EPS (Diluted)2.53(4.83)5.23(1.27)(1.75)
Weighted Avg Shares502M504M506M510M513M
Weighted Avg Shares (Diluted)508M504M506M510M513M

Baxter International Inc.

NYSE:BAX

Intrinsic Alpha fair value

Locked

Current Price

$26.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.